Loading stock data...

Auro Laboratories Limited

BSE: AUROLAB

BSE
220.05 -1.45 (-0.65%)

Prev Close

221.5

Open Price

224.45

Volume

2,223

Today Low / High

220 / 228.75

52 WK Low / High

170 / 303

Range

209 - 231

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 220.05, reflecting a change of -1.45 (-0.65463%). The expected target range on the BSE is 209 - 231. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

17 Oct 224.50 0.22%
16 Oct 218.10 1.56%
15 Oct 216.00 1.60%
14 Oct 212.00 1.89%
13 Oct 230.00 -5.37%
10 Oct 220.95 0.02%
09 Oct 221.05 -0.50%
08 Oct 219.90 0.50%
07 Oct 217.00 1.31%
06 Oct 228.10 -3.33%
03 Oct 238.25 -4.26%
01 Oct 245.00 -2.76%
30 Sep 224.00 5.00%
29 Sep 230.00 3.46%
26 Sep 231.10 -0.22%
25 Sep 239.10 1.86%
24 Sep 236.00 1.95%
23 Sep 247.95 -2.82%
22 Sep 246.00 -1.83%

Auro Laboratories Limited Graph

Auro Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Auro Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 220.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 220.05 222.25 200.03 - 244.48
224.45 179.56 - 269.34
226.65 158.66 - 294.65
Bearish Scenario 220.05 217.85 196.06 - 239.63
215.65 172.52 - 258.78
213.45 149.41 - 277.48

Overview of Auro Laboratories Limited

ISIN

INE292C01011

Industry

Medical - Pharmaceuticals

Vol.Avg

5,628

Market Cap

1,407,921,750

Last Dividend

0

Official Website

Visit Website

IPO Date

2000-11-13

DCF Diff

411.43

DCF

-190

Financial Ratios Every Investor Needs

Stock Rating Details for AUROLAB

Metric Value Recommendation
Overall Rating C- Strong Sell
DCF Score 1 Strong Sell
ROE Score 2 Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 2 Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 19.40 Cr 9.21 Cr 10.19 Cr 0.5254 0.00 Cr 0.00 Cr 2.31 Cr 1.84 Cr 2.95 4.06 Cr 0.0948
2024-03-31 52.70 Cr 27.76 Cr 24.94 Cr 0.4732 0.00 Cr 0.88 Cr 21.54 Cr 7.79 Cr 12.50 10.67 Cr 0.1479
2023-03-31 52.26 Cr 36.73 Cr 15.54 Cr 0.2973 0.00 Cr 0.39 Cr 3.32 Cr 2.44 Cr 3.92 4.39 Cr 0.0467
2022-03-31 50.44 Cr 33.58 Cr 16.86 Cr 0.3342 0.00 Cr 0.35 Cr 3.61 Cr 2.84 Cr 4.56 5.72 Cr 0.0564
2021-03-31 52.93 Cr 29.84 Cr 23.10 Cr 0.4364 0.00 Cr 0.32 Cr 10.21 Cr 7.18 Cr 11.52 12.00 Cr 0.1356

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.00 Cr 99.10 Cr 56.13 Cr 42.9681 Cr 45.01 Cr 45.01 Cr 3.67 Cr 77.53 Cr 0.00 Cr 0.00 Cr 0.05 Cr 21.6416 Cr
2024-03-31 0.99 Cr 85.73 Cr 43.77 Cr 41.9678 Cr 26.24 Cr 25.25 Cr 8.24 Cr 54.83 Cr 0.00 Cr 0.00 Cr -0.42 Cr 23.9345 Cr
2023-03-31 1.79 Cr 55.99 Cr 21.79 Cr 34.2004 Cr 6.41 Cr 4.63 Cr 11.76 Cr 20.28 Cr 1.06 Cr 0.00 Cr -9.67 Cr 18.1310 Cr
2022-03-31 5.21 Cr 54.96 Cr 23.44 Cr 31.5210 Cr 13.78 Cr 8.57 Cr 4.25 Cr 17.28 Cr 1.51 Cr -1.65 Cr -6.52 Cr 20.1306 Cr
2021-03-31 10.82 Cr 41.89 Cr 13.31 Cr 28.5826 Cr 3.16 Cr -7.66 Cr 2.55 Cr 13.69 Cr 0.00 Cr 0.00 Cr -2.95 Cr 9.2357 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 5.7471 Cr -24.4544 Cr 17.6881 Cr -18.0537 Cr -1.0192 Cr 0.6296 Cr -23.8008 Cr 1.8809 Cr 18.7704 Cr 0.0000 Cr 4.5718 Cr
2024-03-31 18.8072 Cr -38.6702 Cr 19.0948 Cr -16.8330 Cr -0.7682 Cr 1.6488 Cr -35.6402 Cr 10.3457 Cr 19.8304 Cr 0.0000 Cr 3.5161 Cr
2023-03-31 3.2812 Cr -5.0813 Cr -8.1785 Cr -0.7930 Cr -9.9787 Cr 2.4170 Cr -4.0742 Cr 3.4457 Cr -7.3643 Cr 0.0000 Cr -7.5012 Cr
2022-03-31 -6.5905 Cr -5.3428 Cr 9.7926 Cr -11.2001 Cr -2.1406 Cr 12.3957 Cr -4.6096 Cr 3.8739 Cr 10.6190 Cr 0.0000 Cr -1.7079 Cr
2021-03-31 12.8156 Cr -3.5079 Cr -0.4556 Cr 12.4406 Cr 8.8522 Cr 14.5363 Cr -0.3751 Cr 10.5054 Cr 0.0028 Cr 0.0000 Cr 1.5159 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 2.77 Cr 0.90 Cr 1.87 Cr 0.6754 -0.24 Cr -0.11 Cr -0.17 0.45 Cr -0.0380
2025-03-31 7.54 Cr 5.16 Cr 2.38 Cr 0.3159 0.65 Cr 0.68 Cr 1.06 0.92 Cr 0.0898
2024-12-31 3.05 Cr 2.28 Cr 0.77 Cr 0.2523 0.17 Cr 0.05 Cr 0.08 0.58 Cr 0.0167
2024-09-30 3.10 Cr 0.06 Cr 3.05 Cr 0.9820 1.99 Cr 0.36 Cr 0.57 1.03 Cr 0.1155
2024-06-30 5.72 Cr 1.74 Cr 3.98 Cr 0.6950 1.05 Cr 0.75 Cr 1.21 1.53 Cr 0.1316

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-06-30 0.00 Cr 0.00 Cr 0.63 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -42.97 Cr
2025-03-31 0.00 Cr 8.45 Cr 8.45 Cr 9.39 Cr 3.67 Cr 21.51 Cr 77.53 Cr 99.10 Cr 56.13 Cr
2024-12-31 0.00 Cr 0.00 Cr 0.69 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -43.37 Cr
2024-09-30 0.07 Cr 8.65 Cr 8.72 Cr 6.78 Cr 7.01 Cr 22.51 Cr 61.47 Cr 84.03 Cr 40.66 Cr
2024-06-30 0.00 Cr 0.00 Cr 0.99 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -41.96 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 -0.11 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 0.68 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 0.05 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 0.36 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 0.75 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹773.00 ₹92,561,877,781.00 ₹123,191.00

Key Executives

Executive Chairman & MD
Mr. Sharat Sahadeolal Deorah B.Com.

Gender: male

Year Born: 1950

Company Secretary & Compliance Officer
Ms. Priyanka Gupta

Gender: female

Year Born:

Whole Time Director
Mr. Siddhartha Sharat Deorah MBA

Gender: male

Year Born: 1978

Additional Whole Time Director
Mr. Kiran Suresh Kulkarni

Gender: male

Year Born: 1971

FAQs about Auro Laboratories Limited

Who is the CEO of the company?

The CEO is Sharat Sahadeolal Deorah.

What is the current market price of the stock?

The current price is ₹225.90.

What is the 52-week price range?

The range is ₹170-303.

What is the market capitalization of the company?

The market capitalization is ₹140.79 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 142.95.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Auro Laboratories Limited (ISIN: INE292C01011) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹140.79 crores and an average daily volume of 5,628 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.